(CercleFinance.com) – The biotechnology company Nanobiotix announces that it will hold an extraordinary general meeting (AGE) on September 1, at 2:00 p.m. CEST at its head office, in application of all the agreements concluded with Johnson & Johnson July 10 last.
On this occasion, it will submit for the approval of its shareholders, the issue of a maximum number of 959,638 shares to be subscribed by Johnson & Johnson Innovation – JJDC, Inc. in return for a first tranche equal to five million dollars. .
As a reminder, in July Nanobiotix signed a global licensing, co-development and marketing agreement with Janssen, a subsidiary of Johnson & Johnson, for NBTXR3, a product-candidate currently being evaluated for various solid tumor indications.